-
Mashup Score: 7‘More options’ flood IBD market as rival IL-23 drugs face off with Stelara biosimilar boom - 3 day(s) ago
A seismic shift is underway for inflammatory bowel disease therapies as a trio of newly approved interleukin-23 inhibitors are poised to challenge both the resident blockbuster and an avalanche of its biosimilars for market dominance in 2025.“IL-23 inhibition is a novel mechanism of action compared with anti-integrin or anti-[tumor necrosis factor] agents,” Sunanda V. Kane, MD,
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0‘More options’ flood IBD market as rival IL-23 drugs face off with Stelara biosimilar boom - 4 day(s) ago
A seismic shift is underway for inflammatory bowel disease therapies as a trio of newly approved interleukin-23 inhibitors are poised to challenge both the resident blockbuster and an avalanche of its biosimilars for market dominance in 2025.“IL-23 inhibition is a novel mechanism of action compared with anti-integrin or anti-[tumor necrosis factor] agents,” Sunanda V. Kane, MD,
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
🗞️ Adults with type 1 #diabetes experiencing recurrent severe hypoglycemia no longer had severe hypoglycemic events after receiving novel islet cell therapy. Learn more about VX-880 and the FORWARD trial 👇 @ATTDconf @PennMedicine #ATTD2025 https://t.co/Z6IKqOrqSm
-
🗞️ Adults with type 1 #diabetes experiencing recurrent severe hypoglycemia no longer had severe hypoglycemic events after receiving novel islet cell therapy. Learn more about VX-880 and the FORWARD trial 👇 @ATTDconf @PennMedicine #ATTD2025 https://t.co/Z6IKqOrqSm